Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
Paratek Pharmaceuticals (Nasdaq: PRTK) announced a conference call on March 14 at 8:30 a.m. EST to provide a corporate update and discuss its fourth quarter and full year 2021 financial results. Investors can access the live audio webcast on the company's website. Paratek is focused on developing life-saving therapies, including its lead product NUZYRA, which targets community-acquired bacterial pneumonia and acute bacterial skin infections. The company also has a collaboration with Zai Lab in China and is exploring opportunities in treating nontuberculous mycobacterial pulmonary disease, estimated at a $1 billion market.
- Paratek's NUZYRA is positioned in a growing market for community-acquired bacterial pneumonia and acute skin infections.
- The collaboration with Zai Lab may enhance market reach in greater China.
- Potential $1 billion addressable market for nontuberculous mycobacterial pulmonary disease.
- The upcoming conference call could reveal disappointing financial results, impacting investor sentiment.
- Market risks associated with dependency on a limited number of key products.
BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.
The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.
Domestic investors wishing to participate in the call should dial: 877-407-0792.
International investors should dial: +1 201-689-8263. The conference ID is 13727320.
Investors can also access the call at https://viavid.webcasts.com/starthere.jsp?ei=1531023&tp_key=373482f150.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to approximately
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
About NUZYRA®
NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains including Y. pestis (plague), and bioterrorism pathogens such as B. anthracis (anthrax).
Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.
Forward Looking Statements
This press release contains forward-looking statements including statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.
| For Investors: | ||
| Hans Vitzthum LifeSci Advisors ir@ParatekPharma.com | ||
| Phone: 617-430-7578 |
For Media:
Christine Fanelle
Scient PR
Christine@scientpr.com
FAQ
What are the financial results Paratek Pharmaceuticals will discuss on March 14, 2022?
What is NUZYRA and its significance for Paratek Pharmaceuticals?
How does Paratek Pharmaceuticals plan to expand its market reach?
What is the potential market for treatments related to nontuberculous mycobacterial disease?
